About EVISTA NORDIC FUSION
EVISTA NORDIC FUSION is a raloxifene hydrochloride formulation designed for in-vitro research applications investigating selective estrogen receptor modulator (SERM) mechanisms. Raloxifene HCl is a benzothiophene derivative that demonstrates tissue-selective estrogen receptor activity, functioning as an antagonist in breast and endometrial tissues while maintaining agonist activity in bone tissue according to preclinical studies. Researchers at Stroid UK Shop utilise this compound to examine estrogen receptor pathway modulation and tissue-specific responses in controlled laboratory environments.
Laboratory Research Applications
This raloxifene hydrochloride preparation enables comprehensive investigation of SERM activity across multiple tissue types. Research teams study its interaction with estrogen receptor alpha and beta subtypes, examining differential gene expression patterns in various cell lines. The compound’s unique pharmacological profile allows scientists to investigate bone mineralisation pathways while simultaneously evaluating protective mechanisms against estrogen-sensitive tissue proliferation. Laboratories incorporate EVISTA NORDIC FUSION into studies examining osteoporosis prevention models, cardiovascular protection research, and endometrial safety profiles. Researchers working with aromatase inhibitors and raloxifene compounds frequently compare this SERM’s activity against other estrogen pathway modulators. The formulation proves valuable for investigating post-menopausal hormone replacement alternatives and examining tissue-selective estrogen receptor signalling cascades in controlled research settings.
Analytical Specifications
| Parameter | Specification |
|---|---|
| Active Compound | Raloxifene Hydrochloride |
| CAS Number | 82640-04-8 |
| Molecular Formula | C₂₈H₂₇NO₄S·HCl |
| Molecular Weight | 510.05 g/mol |
| Storage Requirements | Room temperature, dry environment |
| Solubility | DMSO, ethanol (verify with supplier) |
Research teams studying metabolic pathways often combine raloxifene investigations with SARM research to examine tissue-selective receptor interactions. Laboratories examining peptide-hormone interactions frequently incorporate peptide compounds alongside SERM studies to investigate comprehensive endocrine pathway modulation. The Nordic Fusion formulation provides consistent results across extended research periods when stored according to specifications.
Research Compliance Statement
EVISTA NORDIC FUSION is manufactured exclusively for in-vitro laboratory research purposes and is not intended for human consumption, therapeutic use, or clinical application. Research institutions and qualified laboratories should handle this compound according to standard safety protocols for investigational substances. All studies involving this raloxifene hydrochloride preparation must comply with institutional review board guidelines and applicable research regulations. This product is intended solely for advancing scientific understanding of selective estrogen receptor modulator mechanisms through controlled laboratory investigation.
